Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171433 | 1.00 | BACE1 (0.37) | BACE1BACE2KDM1AMAOBBDKRB1 | |
| SCHEMBL2631677 | 1.00 | BACE1 (0.37) | BACE1BACE2KDM1AMAOBBDKRB1 | |
| SCHEMBL2631720 | 1.00 | BACE1 (0.37) | BACE1BACE2KDM1AMAOBBDKRB1 | |
| SCHEMBL2620058 | 1.00 | BACE1 (0.37) | BACE1BACE2KDM1AMAOBBDKRB1 | |
| SCHEMBL2631717 | 0.91 | BACE1 (0.37) | BACE1BACE2KDM1AMAOB | |
| SCHEMBL2620060 | 0.91 | BACE1 (0.37) | BACE1BACE2KDM1AMAOB | |
| SCHEMBL2631675 | 0.91 | BACE1 (0.37) | BACE1BACE2KDM1AMAOB | |
| SCHEMBL15171755 | 0.91 | BACE1 (0.37) | BACE1BACE2KDM1AMAOB | |
| SCHEMBL13009642 | 0.91 | BACE1 (0.37) | BACE1BACE2KDM1AMAOB | |
| SCHEMBL2619946 | 0.91 | BACE1 (0.38) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885KDM1A 1829/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885KDM1A 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.